[et_pb_section fb_built=”1″ admin_label=”Hero section” _builder_version=”4.19.4″ _module_preset=”default” background_image=”https:\/\/tonetx.eu\/wp-content\/uploads\/2023\/02\/iStock-696241690-scaled.jpg” background_position=”top_right” background_vertical_offset=”29%” custom_margin=”|||” custom_padding=”10%||10%|” global_colors_info=”{}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” custom_margin=”|||” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”1px|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_cta title=”vision” button_url=”#” _builder_version=”4.17.4″ _module_preset=”default” header_level=”h1″ header_font=”Lato|900||on|||||” header_font_size=”80px” header_letter_spacing=”2px” header_line_height=”1.2em” body_font=”Lato||||||||” body_font_size=”20px” body_line_height=”1.8em” use_background_color=”off” custom_button=”on” button_text_size=”16px” button_text_color=”#ffffff” button_bg_color=”#fa7f28″ button_border_width=”6px” button_border_color=”#fa7f28″ button_border_radius=”5px” button_letter_spacing=”2px” button_font=”Lato|900||on|||||” text_orientation=”left” max_width=”750px” module_alignment=”left” animation_style=”fold” animation_intensity_fold=”16%” header_font_size_tablet=”46px” header_font_size_phone=”” header_font_size_last_edited=”on|tablet” header_text_shadow_style=”preset1″ header_text_shadow_blur_strength=”0.6em” header_text_shadow_color=”rgba(0,0,0,0.6)” box_shadow_style_button=”preset3″ box_shadow_blur_button=”30px” box_shadow_spread_button=”8px” box_shadow_color_button=”rgba(250,127,40,0.15)” button_letter_spacing_hover=”2px” global_colors_info=”{}” button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”on” button_letter_spacing__hover=”2px” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Features” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 0%|#e8eefc 100%” background_color_gradient_start=”#ffffff” background_color_gradient_end=”#e8eefc” custom_padding=”100px|0px|100px|0px” global_colors_info=”{}”][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” background_color=”#ffffff” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||30px||false|false” custom_padding=”||||false|false” animation_style=”slide” animation_direction=”bottom” animation_intensity_slide=”6%” animation_starting_opacity=”100%” border_radii=”on|15px|15px|15px|15px” border_color_all=”gcid-0881eb85-6db4-495d-84c3-350d3a9274f0″ border_width_top=”18px” box_shadow_style=”preset3″ box_shadow_vertical=”39px” box_shadow_blur=”80px” box_shadow_color=”rgba(0,0,0,0.1)” custom_width_px=”1280px” locked=”off” global_colors_info=”{%22gcid-0881eb85-6db4-495d-84c3-350d3a9274f0%22:%91%22border_color_all%22%93}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”30px|40px|30px|40px” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.4″ _module_preset=”default” text_font=”Arial||||||||” text_text_color=”#1d1d1b” text_font_size=”15px” text_line_height=”2em” header_font=”||||||||” header_2_font=”Josefin Sans|700|||||||” header_2_text_color=”#b5bf0e” header_2_font_size=”42px” header_2_line_height=”1.5em” text_orientation=”center” max_width=”1128px” module_alignment=”center” custom_margin=”|-206px||-131px||” locked=”off” global_colors_info=”{}”]<\/p>\n
T-One<\/em><\/strong> Therapeutics<\/em><\/strong> goal relies on the identification and preclinical development of new RNA-based therapeutic strategies to treat tumors and autoimmune diseases for future use in standard immunotherapy care.<\/p>\n It is known that T lymphocytes infiltrating pathological tissues often become exhausted i.e. dysfunctional once reached the site of the disease. Fully functional T lymphocytes are necessary to block tumor onset and progression.<\/p>\n Similarly, a balanced and controlled immune response is needed to improve or prevent autoimmune and inflammatory diseases. Recently different immunotherapies have been developed to promote tumor clearance by boosting effector functions mediated by T lymphocytes.<\/p>\n Despite very promising results, a high fraction of patients do not respond to immunotherapy, while other patients even develop severe adverse events. Therefore, novel and safer immunotherapies or therapeutic adjuvants are urgently needed to increase patients\u2019 responsiveness and improve patients\u2019 outcome.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.19.4″ _module_preset=”default” background_color=”#ffffff” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||30px||false|false” custom_padding=”0px|0px|0px|0px|false|false” animation_style=”slide” animation_direction=”bottom” animation_intensity_slide=”6%” animation_starting_opacity=”100%” border_radii=”on|15px|15px|15px|15px” border_color_all=”gcid-0881eb85-6db4-495d-84c3-350d3a9274f0″ border_width_top=”18px” box_shadow_style=”preset3″ box_shadow_vertical=”39px” box_shadow_blur=”80px” box_shadow_color=”rgba(0,0,0,0.1)” custom_width_px=”1280px” locked=”off” global_colors_info=”{%22gcid-0881eb85-6db4-495d-84c3-350d3a9274f0%22:%91%22border_color_all%22%93}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”30px|40px|30px|40px” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.19.4″ _module_preset=”default” text_font=”Arial||||||||” text_text_color=”#1d1d1b” text_font_size=”15px” text_line_height=”2em” header_font=”||||||||” header_2_font=”Josefin Sans|700|||||||” header_2_text_color=”#b5bf0e” header_2_font_size=”42px” header_2_line_height=”1.5em” header_3_text_align=”left” max_width=”1128px” module_alignment=”center” custom_margin=”|-206px||-131px||” hover_enabled=”0″ locked=”off” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n How to revert T lymphocytes exhausted phenotype \u2013 the use of LINE1-ASOs:<\/strong><\/p>\n The RNA transcribed from LINE1 repetitive elements (LINE1-RNA), by accumulating in the nucleus of Tumor Infiltrating Lymphocytes, impairs their immunological effector functions.<\/p>\n LINE1-ASOs, destroying these RNAs, are able to restore T lymphocytes activity enhancing their immunological response, therefore representing a novel therapeutic approach to fight tumors as well as autoimmune diseases.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Hero section” _builder_version=”4.19.4″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(150,105,97,0.67) 0%|rgba(2,0,76,0.84) 100%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”rgba(150,105,97,0.67)” background_color_gradient_end=”rgba(2,0,76,0.84)” background_image=”https:\/\/tonetx.eu\/wp-content\/uploads\/2023\/02\/iStock-696241690-scaled.jpg” background_position=”bottom_center” background_vertical_offset=”56%” custom_margin=”|||” custom_padding=”10%||10%|” locked=”off” global_colors_info=”{}”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" VISION T-One Therapeutics goal relies on the identification and preclinical development of new RNA-based therapeutic strategies to treat tumors and autoimmune diseases for future use in standard immunotherapy care. It is known that T lymphocytes infiltrating pathological tissues often become exhausted i.e. dysfunctional once reached the site of the disease. Fully functional T lymphocytes are […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-353","page","type-page","status-publish","hentry"],"yoast_head":"\n